Skip to main content
Devi SenGupta

Devi SenGupta

Industry Collaboration Group member since 2022
Global Lead, HIV Cure Development
Executive Director, Virology Therapeutic Area
Gilead Sciences, Inc.
Foster City, CA, USA

Devi SenGupta, MD, MPhil, is Executive Director of Clinical Development at Gilead Sciences, leading the company’s HIV cure development programme. Before joining Gilead in 2015, she was a physician scientist leading translational HIV immunology research as an Assistant Professor at the University of California, San Francisco (UCSF). Her NIH-funded programme focused on identifying novel strategies to enhance cellular immunity against HIV. Devi received her Bachelor of Arts in psychology and biology at Harvard University, M Phil. in neuropsychology at Cambridge University, UK, and MD at the University of Washington School of Medicine. She completed her internal medicine residency at Johns Hopkins Hospital and infectious diseases fellowship at UCSF. During her time at Gilead, she has led multiple HIV treatment, HIV cure and COVID-19 trials. As head of the HIV cure programme, Devi provides strategic direction for cross-functional internal teams and external multistakeholder collaborations developing combination approaches aimed at achieving long-term HIV remission.

The IAS promotes the use of non-stigmatizing, people-first language. The translations are all automated in the interest of making our content as widely accessible as possible. Regretfully, they may not always adhere to the people-first language of the original version.